- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT01890772
Vitamin D + Telaprevir + Peginterferon + Ribavirin for of Hepatitis C Genotype 1
A Pilot Trial of the Safety and Efficacy of Telaprevir +Peginterferon +Ribavirin +Vitamin D3 Among Treatment-naive Veterans Infected With Genotype 1 Hepatitis C Virus
This study is for people who have been diagnosed with chronic hepatitis C, specifically those who have a certain type of the virus, genotype 1, and who have not yet received treatment for hepatitis C. This pilot study is designed to test whether the addition of vitamin D, to the three drugs (Incivek (telaprevir), Pegasys (peginterferon alfa-2a), and ribavirin) that are approved by the Food and Drug Administration (FDA) for the treatment of hepatitis C, can help eliminate the HCV from the body. Currently, doctors are unsure if the addition of vitamin D to prescribed hepatitis C therapy will have any effects on how the body clears the virus.
Once enrolled, participants will be randomly assigned (like flipping a coin) to receive telaprevir + peginterferon alfa-2a + ribavirin + vitamin D3 (treatment group) or telaprevir + peginterferon alfa-2a + ribavirin (control group). A total of 80 participants, of all races/ethnicities, will be included in this study, at 5 to 10 VA hospital study sites (10 - 20 participants/site).
Participants assigned to the treatment group will begin a lead-in phase where they will receive 5,000 IU of vitamin D3 per day. Every two weeks during the lead-in phase, participants will be tested to determine the Vitamin D level in their blood, as well as other tests, including HCV RNA (to determine the amount of virus present) and calcium levels. Once an adequate level of Vitamin D is detected in participants' blood, participants will begin treatment with telaprevir + peginterferon alfa-2a + ribavirin + vitamin D3 (15,000 IU/week) for 12 weeks.
Participants randomized to the control group will immediately begin treatment with telaprevir + peginterferon alfa-2a + ribavirin for 12 weeks. At the end of Week 12 the participants' involvement in the study will be complete.
Adverse events and effects of vitamin D3 will be obtained by assessing participants' medical history, physical examination, and blood tests at clinic visits. HCV RNA will be assessed at Screening, Day 1, Week 2, 4, 8 and 12.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Tipo di studio
Fase
- Fase 2
- Fase 3
Contatti e Sedi
Luoghi di studio
-
-
California
-
Long Beach, California, Stati Uniti, 90822
- VA Long Beach Healthcare System
-
-
Minnesota
-
Minneapolis, Minnesota, Stati Uniti, 55417
- Minneapolis VAHCS
-
-
Missouri
-
Kansas City, Missouri, Stati Uniti, 64128
- Kansas City VA Medical Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Stati Uniti, 19104
- Philadelphia VA Medical Center
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Chronic Hepatitis C genotype 1 infection
- Treatment naïve
- Age >18 years
- Agree to genetic testing
Exclusion Criteria:
- Liver disease other than from hepatitis C
- HCV infection with mixed genotypes
- Decompensated liver disease
- AFP>100ng/ml.
- Known HIV infection
- Serum 25(OH)D less than 12ng/ml or greater than 30ng/ml
- Regular vitamin D supplement use
- Regular calcium supplement use
- Refusal to abstain from vitamin D supplementation
- Current or past history of kidney stones
- Current use of any of the prohibited medications listed in section 5.5 and the INCIVEK® package insert.
- Need for therapeutic vitamin D or calcium (e.g. treatment for osteoporosis, osteomalacia, hyperparathyroidism etc.), in the opinion of the investigator
- Significant substance abuse within the past 6 months,
- Suicidal attempt in the past 10 years or suicidal ideation in past 3 months, or any other psychiatric condition that the investigator deems would make a subject unsuited for treatment with peginterferon or ribavirin.
- Confirmed or suspected malignancy, or history of malignancy within the past 3 years (except treated basal cell carcinoma of the skin or in situ carcinoma of the uterine cervix)
- Any autoimmune disease not easily controlled (in the opinion of the investigator)
- Any condition resulting in malabsorption (
- Poorly controlled thyroid disorder, or diabetes mellitus (HbA1c > 9)
- Glomerular diseases (e.g., glomerulosclerosis or glomerulonephritis) associated with a serum creatinine >1.5 times the upper limit of normal
- Current or history of any clinically significant cardiac abnormalities/dysfunction (eg, angina, congestive heart failure, myocardial infarction, pulmonary hypertension, complex congenital heart disease, cardiomyopathy, significant arrhythmia) including current uncontrolled hypertension or history of use of antianginal agents for cardiac conditions (Inclusion will be considered if clearance by a cardiologist is obtained.)
- Receipt of an investigational drug within the past 30 days
- Females who have a positive pregnancy test at the time of screening, are breastfeeding or who anticipate pregnancy within the next 18 months, or men with pregnant partners
- Lack of agreement from subject to use two forms of acceptable contraception
- History or other evidence of any significant illness which, in the opinion of the investigator, would make the patient, unsuitable for the study
- Laboratory Exclusions
Hemoglobin: <12gm/dl male or female
Neutrophil: <1,200/mm3
Platelets: <90,000/mm3
INR: >1.5
Albumin: <3.2gm/dl
Total Bilirubin: >2.0mg/dl
HbA1c: >9.5%
Serum Creatinine: >1.5 times the upper limit of normal
Serum Calcium Within local laboratory normal range
Parathyroid hormone (PTH) <10 or >55 pg/mL
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Comparatore attivo: VitD+telaprevir+peginterferon+ribavirin
Participants randomized to the treatment group will receive 5,000IU/day of vitamin D3 during the lead-in phase.
When the serum 25(OH)D level is ≥35ng/ml the participant will begin telaprevir + vitamin D3 (15,000IU/week) + peginterferon alfa-2a (180ug/week) + weight based ribavirin treatment.
|
Altri nomi:
Altri nomi:
|
Comparatore attivo: Telaprevir + Peginterferon + Ribavirin
Participants randomized to the control group immediately begin treatment with telaprevir + 180ug of peginterferon alfa-2a (Pegasys) per week and either weight based ribavirin.
|
Altri nomi:
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
HCV RNA
Lasso di tempo: 4 weeks
|
Hepatitis C virus Ribonucleic Acid identifies the presence of Hepatitis C in the blood
|
4 weeks
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
adverse event profile
Lasso di tempo: 12 weeks
|
Cumulative record of unanticipated or unintended medical occurrences, not necessarily related to the study treatment.
|
12 weeks
|
Collaboratori e investigatori
Sponsor
Collaboratori
Investigatori
- Investigatore principale: Timothy R Morgan, MD, Veterans Affairs Long Beach Healthcare
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Anticipato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Malattie dell'apparato digerente
- Infezioni da virus a RNA
- Malattie virali
- Infezioni
- Infezioni a trasmissione ematica
- Malattie trasmissibili
- Malattie del fegato
- Flaviviridae Infezioni
- Epatite, virale, umana
- Infezioni da enterovirus
- Infezioni da Picornaviridae
- Epatite
- Epatite A
- Epatite C
- Effetti fisiologici delle droghe
- Meccanismi molecolari dell'azione farmacologica
- Agenti antinfettivi
- Agenti antivirali
- Antimetaboliti
- Micronutrienti
- Vitamine
- Agenti di conservazione della densità ossea
- Ribavirina
- Peginterferone alfa-2a
- Vitamina D
Altri numeri di identificazione dello studio
- 1217
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Vitamina D
-
Alcon ResearchCompletato
-
Johns Hopkins UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletatoVitamina D come modificatore dell'epcidina sierica nei bambini con malattia renale cronica (D-fense)Anemia da malattia renale cronicaStati Uniti
-
Boston Children's HospitalCompletato
-
Royal Prince Alfred Hospital, Sydney, AustraliaCompletatoColonscopiaAustralia
-
Rhode Island HospitalVirtually Better, Inc.CompletatoSalute mentale | Virus dell'immunodeficienza umanaStati Uniti
-
GlaxoSmithKlineCompletato
-
Johns Hopkins UniversityNational Institute of Allergy and Infectious Diseases (NIAID)Non ancora reclutamento
-
University of AarhusNovo Nordisk A/S; Aarhus University Hospital; AP Moeller Foundation; Danish Diabetes...ReclutamentoInvecchiamento | Disturbo del metabolismo | Chetonemia | Disturbo muscolareDanimarca
-
University Medical Center GroningenMaastricht University Medical Center; UMC Utrecht; Academisch Medisch Centrum -... e altri collaboratoriCompletato
-
Daewoong Pharmaceutical Co. LTD.Non ancora reclutamento